GlaxoSmithKline Pharmaceuticals Limited (GLAXO) AI Stock Analysis

• Market Cap: ₹410.56B
• Dividend Yield: 2.16%
• Average Volume (3M): 1.83K
• Price to Earnings (P/E): 35.4
• Beta (1Y): 0.73
• Revenue Growth: 4.17%
• EPS Growth: 41.51%
• Country: IN
• Employees: 3,211
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 16.70
• Shares Outstanding: 169,406,040
• 10 Day Avg. Volume: 1,472
• 30 Day Avg. Volume: 1,831
• PEG Ratio: 0.89
• Price to Book (P/B): 24.29
• Price to Sales (P/S): 12.64
• P/FCF Ratio: 37.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 61.38
• Revenue Forecast (FY): ₹38.91B

• Rating: 63 Neutral
• Price Target: ₹2,516.00 ▲(1.31% Upside)
• Action: Reiterated Date: 10/28/25
• Date: Action: Reiterated 10/28/25

GlaxoSmithKline Pharmaceuticals Limited's strong financial performance is the most significant factor, showcasing robust profitability and efficient cash flow management. However, the technical analysis indicates bearish momentum, and the high P/E ratio suggests potential overvaluation. The absence of earnings call data and corporate events limits further insights.

Positive Factors

Balance sheet strength

Extremely low leverage and strong ROE indicate durable financial resilience. With minimal debt and substantial cash reserves the company can fund R&D, absorb tender volatility, and pursue strategic investments without refinancing, supporting stability over the next several months.

Cash generation

Very strong free cash flow growth and operating cash conversion demonstrate persistent internal funding capacity. High FCF supports capex, dividend/payout flexibility, and reinvestment in product launches, enabling the business to sustain operations and strategic programs over a multi-month horizon.

Margin profile

High and stable margins reflect pricing power and operational efficiency in branded pharmaceuticals. Healthy gross and net margins provide buffer against cost shocks and support reinvestment into marketing and development, underpinning durable profitability across 2–6 months.

Negative Factors

Recent revenue momentum

A recent low growth metric suggests sales momentum has moderated versus longer-run trends. Slower near-term top-line expansion raises the bar for new product launches or market share gains to sustain earnings growth and could pressure strategic investment pacing over the coming months.

Regulated pricing exposure

Significant exposure to regulated channels and tender procurement creates structural revenue and margin variability. Pricing controls and import cost sensitivity can compress margins and make cash flows contingent on policy and tender cycles, reducing predictability over medium term.

Limited public disclosure

Absence of earnings call detail and limited corporate-event disclosure reduces visibility into pipeline progress, guidance and management priorities. That opacity makes it harder to assess execution risks and product timelines, hindering clear fundamental assessment over 2–6 months.

GlaxoSmithKline Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

How the Company Makes Money

GLAXO generates revenue primarily through the sale of its pharmaceutical products, vaccines, and consumer healthcare items. The Pharmaceuticals segment contributes significantly to revenue through prescription drugs that treat various diseases and conditions. The Vaccines division profits from the distribution of immunizations globally, often supported by government contracts and public health initiatives. Additionally, the Consumer Healthcare sector provides over-the-counter products, which are sold directly to retailers and consumers. Key revenue streams include direct sales to hospitals and pharmacies, long-term agreements with healthcare providers, and collaborations with other pharmaceutical companies for joint research and product development. Strategic partnerships and licensing agreements further enhance revenue potential, allowing GLAXO to expand its market reach and innovate within the competitive healthcare landscape.

GlaxoSmithKline Pharmaceuticals Limited Financial Statement Overview

Summary

GlaxoSmithKline Pharmaceuticals Limited exhibits a strong financial profile with impressive revenue growth, robust profitability, and efficient cash flow management. The company maintains a solid balance sheet with low leverage and high liquidity, positioning it well for future opportunities and challenges in the pharmaceutical industry.

Income Statement

GlaxoSmithKline Pharmaceuticals Limited shows strong financial performance with a consistent increase in total revenue over the years. For the latest fiscal year, the company achieved a Gross Profit Margin of 62.88% and a Net Profit Margin of 24.74%, indicating healthy profitability. The Revenue Growth Rate was 8.92%, showcasing robust top-line growth. Additionally, the company reported a solid EBIT Margin of 47.45% and an EBITDA Margin of 31.40%, reflecting efficient operational management.

Balance Sheet

The balance sheet demonstrates a strong financial position with a low Debt-to-Equity Ratio of 0.005, suggesting minimal financial leverage. The Return on Equity (ROE) stands at 47.53%, indicating efficient use of equity to generate profits. The Equity Ratio of 47.50% highlights a balanced capital structure. The company maintains substantial liquidity, evidenced by significant cash reserves.

Cash Flow

The cash flow analysis reveals positive trends with a substantial Free Cash Flow Growth Rate of 129.96% in the latest fiscal year. The Operating Cash Flow to Net Income Ratio is 1.39, suggesting strong cash generation relative to net income. Additionally, the Free Cash Flow to Net Income Ratio is 1.37, reflecting robust cash flow management and the ability to support ongoing operations and investments.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	37.09B	37.49B	34.54B	32.52B	32.78B	29.26B
Gross Profit	21.76B	23.35B	20.99B	19.48B	19.00B	16.43B
EBITDA	12.33B	11.53B	8.81B	7.88B	7.43B	5.73B
Net Income	9.55B	9.28B	5.90B	6.11B	16.95B	3.58B
Balance Sheet
Total Assets	36.65B	41.08B	35.57B	33.27B	46.33B	31.13B
Cash, Cash Equivalents and Short-Term Investments	20.61B	24.98B	18.57B	16.54B	29.03B	11.63B
Total Debt	357.10M	99.50M	186.65M	155.40M	200.76M	346.27M
Total Liabilities	19.57B	21.57B	17.79B	15.85B	19.70B	16.14B
Stockholders Equity	17.08B	19.51B	17.78B	17.41B	26.63B	14.78B
Cash Flow
Free Cash Flow	1.67B	12.67B	5.51B	4.40B	7.76B	5.34B
Operating Cash Flow	1.84B	12.90B	5.82B	4.84B	8.11B	5.78B
Investing Cash Flow	3.40B	-458.10M	87.12M	8.08B	-4.06B	4.19B
Financing Cash Flow	-7.23B	-7.69B	-5.61B	-15.43B	-5.24B	-6.96B

GlaxoSmithKline Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2483.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLAXO, the sentiment is Negative. The current price of 2483.35 is below the 20-day moving average (MA) of 2554.57, above the 50-day MA of 2479.51, and below the 200-day MA of 2759.91, indicating a bearish trend. The MACD of -10.17 indicates Positive momentum. The RSI at 39.09 is Neutral, neither overbought nor oversold. The STOCH value of 23.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:GLAXO.

GlaxoSmithKline Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUNPHARMA	73 Outperform	₹4.32T	30.62	―	0.91%	9.26%	-5.47%
LUPIN	72 Outperform	₹1.06T	20.49	―	0.57%	15.49%	64.37%
DRREDDY	70 Outperform	₹1.08T	21.88	―	0.63%	14.10%	9.72%
CIPLA	68 Neutral	₹1.06T	45.14	―	0.87%	6.93%	21.55%
TORNTPHARM	66 Neutral	₹1.49T	51.30	―	0.84%	9.11%	18.76%
GLAXO	63 Neutral	₹410.56B	35.44	―	2.16%	4.17%	41.51%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

GlaxoSmithKline Pharmaceuticals Limited Corporate Events

GSK Pharma India Publishes Postal Ballot Notice Advertisements in Line With LODR Norms

GlaxoSmithKline Pharmaceuticals Limited has notified the stock exchanges that it has published newspaper advertisements regarding a postal ballot notice, in compliance with Regulation 47 of the Listing Obligations and Disclosure Requirements Regulations, 2015. The move reflects the company’s ongoing adherence to corporate governance and disclosure norms as it seeks shareholder approval on matters placed through the postal ballot process, underscoring its commitment to regulatory transparency and investor communication.

GSK Pharma India Seeks Shareholder Nod on CFO Appointment via E‑Voting

GlaxoSmithKline Pharmaceuticals Limited has initiated a postal ballot process to seek shareholder approval for the appointment and remuneration of Mr. Ronojit Biswas as Whole-time Director and Chief Financial Officer. The move, conducted entirely via electronic remote e-voting in line with MCA and SEBI regulations, underscores the company’s adherence to digital governance standards and formalizes a key leadership role that is material for its financial management and listed-company compliance.

The company has engaged KFin Technologies to provide the e-voting platform, with voting open from March 9 to April 8, 2026, and results to be announced on or before April 10, 2026. The outcome will be reported to BSE and NSE and posted on the company’s website, ensuring transparency for investors as they weigh in on a significant board-level financial appointment.

GSK Pharma India Seeks Shareholder Nod for CFO Appointment via E-Voting Postal Ballot

GlaxoSmithKline Pharmaceuticals Limited has initiated a shareholder approval process via an electronic postal ballot to confirm the appointment and remuneration of Mr. Ronojit Biswas as Whole-time Director and Chief Financial Officer. The move underscores the company’s focus on strengthening its top management and financial oversight, a key consideration for investors assessing governance and leadership continuity.

The postal ballot will be conducted exclusively through remote e-voting, with electronic notices sent to shareholders whose email addresses are registered with the company or depositories as of the specified cut-off date. Voting runs from 9 March to 8 April 2026, after which an independent scrutinizer will verify the results, which will be disclosed to the stock exchanges and posted on the company’s and e-voting provider’s websites, reinforcing transparency in the decision-making process.

GSK Pharma India Names Ronojit Biswas as New CFO Amid Leadership Transition

GlaxoSmithKline Pharmaceuticals Limited has announced that its board has approved the appointment of Ronojit Biswas as Whole-Time Director and Chief Financial Officer for a three-year term starting April 1, 2026. Biswas, a veteran GSK finance executive with over 25 years of global experience across India, Vietnam, Singapore, Brazil, and the UK, brings deep expertise in financial reporting, performance management, and internal controls.

The current CFO, Juby Chandy, will step down as Whole-Time Director and CFO effective March 11, 2026, following his promotion to lead APAC Finance within the wider GSK group. The company has credited Chandy with strengthening its financial position, improving governance, and executing key transformation priorities, signaling a continuity-focused leadership transition that may support stable financial stewardship and reinforce GSK’s governance standards in India.

GSK Pharma India Names Ronojit Biswas CFO as Juby Chandy Moves to APAC Role

GlaxoSmithKline Pharmaceuticals Limited has announced a leadership change in its finance function, appointing Ronojit Biswas as Whole-Time Director and Chief Financial Officer for a three-year term starting 1 April 2026. Biswas, a long-serving GSK executive, brings over 25 years of international finance experience across markets such as India, Vietnam, Singapore, Brazil and the UK, reinforcing the company’s focus on experienced internal talent for critical roles.

He succeeds current CFO and Whole-Time Director Juby Chandy, who will step down from these roles on 11 March 2026 to take up a new position leading APAC Finance within the wider GSK group. The transition underscores GSK’s emphasis on continuity in financial stewardship, governance and strategic execution, while signalling the importance of the India business within the group’s regional and global leadership structure.

GSK Pharma Says Surge in Share Trading Volumes Is Market-Driven, Affirms Full Regulatory Compliance

GlaxoSmithKline Pharmaceuticals Limited has responded to queries from stock exchanges regarding a recent sharp increase in trading volumes of its shares, stating that it has fully complied with all disclosure requirements under SEBI’s listing regulations and has not withheld any material or price-sensitive information that could affect its operations or performance. The company emphasized that the spike in trading activity is purely market driven and reiterated its commitment to continue informing the exchanges of any future price-sensitive developments, aiming to reassure investors and regulators about the transparency of its disclosures and governance practices.